Article Text

Download PDFPDF
ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients
  1. J M van Dieren,
  2. A J van Vuuren,
  3. J G Kusters,
  4. E E S Nieuwenhuis,
  5. E J Kuipers,
  6. C J van der Woude
  1. Erasmus MC, University Medical Centre Rotterdam, the Netherlands
  1. Correspondence to:
    MsJ M van Dieren
    Erasmus MC, University Medical Centre Rotterdam, Dr Molewaterplein 40 room, Ba 393 Rotterdam, the Netherlands; j.vandierenerasmusmc.nl

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the letter by Colombel et al on the non-predictive value of ITPA genotyping for the development of myelosuppression after azathioprine (AZA) treatment (Gut 2005;54:565).

The level of thiopurine methyltransferase (TPMT) activity is determined by a common genetic polymorphism.1 It was shown that low TPMT activity is linked to a higher relative risk of development of myelosuppression after AZA treatment.2 Testing for TPMT genotype before the start of AZA treatment is of limited clinical value as myelosuppression resulting from TPMT mutations occurs in less then one third of patients with myelosuppression.3

Polymorphisms in genes encoding inosine triphosphate …

View Full Text

Footnotes

  • Conflict of interest: None declared.

Linked Articles